ArticleInternational journal of environmental research and public health2022
Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999-2018.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis.BMC complementary medicine and therapies · 2025Pooled it
- Association of anxiety, depressive symptoms, and inflammatory indices with cardiometabolic multimorbidity.Brain, behavior, & immunity - health · 2026Article
- Temporal Trends and Disparities in Type 2 Diabetes Mellitus and Congestive Heart Failure Mortality in the United States From 1999-2020: A CDC WONDER Analysis.Health science reports · 2026Article
- Neutrophil-to-high-density lipoprotein cholesterol ratio and prevalent cardiometabolic multimorbidity in older adults: an exploratory cross-sectional analysis.BMC endocrine disorders · 2026Article
- Associations of three metabolic biomarkers with the risk of cardiometabolic multimorbidity: a national prospective study.Lipids in health and disease · 2026Article
- A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit.Cardiology and therapy · 2026Review
- Cardiometabolic multimorbidity prevalence and its socio-demographic determinants among Iranian adults: insights from the nationwide STEPS 2021.Scientific reports · 2026Article
- Joint association of atherogenic index of plasma (AIP) and body roundness index (BRI) with cardiometabolic multimorbidity in adults in Guangzhou, China.Cardiovascular diabetology · 2026Article
- Association between hearing impairment and cardiometabolic multimorbidity among middle-aged and older adults in China.Scientific reports · 2026Article
- Life's Essential 8 and healthy longevity among people with and without cardiometabolic multimorbidity: A prospective study of UK Biobank.American journal of preventive cardiology · 2026Article
- Cord blood metabolomics: a window into future heart health.Pediatric research · 2026Article
- Describing the Profile of Individuals at Heightened Risk for Cardiometabolic Multimorbidity: A Secondary Analysis of the Canadian Longitudinal Study on Aging Data.American journal of health promotion : AJHP · 2026Observational
- Association between body roundness index trajectories and the risk of cardiometabolic multimorbidity in Chinese middle-aged and older adults: Evidence from the China health and retirement longitudinal study.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Change in loneliness and subsequent cardiometabolic Multimorbidity among middle-aged and older adults: results from two east asian prospective cohorts.Aging clinical and experimental research · 2026Article
- Pulse pressure and cardiometabolic disease progression: associations with incident multimorbidity and mortality in UK biobank.Frontiers in cardiovascular medicine · 2026Article
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome.JACC. Advances · 2026Article
- The trajectories of cardiometabolic multimorbidity associate with mortality risk: a study based on Guangdong adult chronic diseases and risk factors cohort.Frontiers in public health · 2026Article
- The associations of the triglyceride-glucose index and estimated glucose disposal rate with incident cardiometabolic multimorbidity vary across obesity phenotypes: a longitudinal cohort study.Frontiers in nutrition · 2026Article
- The association between HbA1c/HDL-C ratio and cardiometabolic multimorbidity among middle-aged and older adults: data from two national prospective cohorts in the United Kingdom and United States.Frontiers in nutrition · 2026Article
- Comparison of the correlation between triglyceride-glucose index and homeostasis model assessment of insulin resistance with subclinical left ventricular dysfunction.Journal of diabetes investigation · 2026Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiometabolic multimorbidity (co-existence of ≥1 cardiometabolic diseases) is increasingly common, while its prevalence in the U.S. is unknown. We utilized data from 10 National Health and Nutrition Examination Survey (NHANES) two-year cycles in U.S. adults from 1999 to 2018. We reported the age-standardized prevalence of cardiometabolic multimorbidity in 2017-2018 and analyzed their trends during 1999-2018 with joinpoint regression models. Stratified analyses were performed according to gender, age, and race/ethnicity. In 2017-2018, the prevalence of cardiometabolic multimorbidity was 14.4% in the U.S., and it was higher among male, older, and non-Hispanic Black people. The three most common patterns were hypertension and diabetes (7.5%); hypertension, diabetes, and CHD (2.2%); and hypertension and CHD (1.8%). During 1999-2018, the prevalence of cardiometabolic multimorbidity in U.S. adults increased significantly, with an averaged two-year cycle percentage change (AAPC) of 3.6 (95% CI: 2.1 to 5.3). The increasing trend was significant for both genders, most age groups except for 60-79 years, and non-Hispanic White people. For common patterns, the trend was increasing for hypertension and diabetes and hypertension, diabetes, and CHD, while it was decreasing for hypertension and CHD. Our findings provide evidence that cardiometabolic multimorbidity has risen as an austere issue of public health in the U.S.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.